[A18-54] Bosutinib (pretreated chronic myelogenous leukaemia) - Benefit assessment according to §35a Social Code Book V
Last updated 03.12.2018
Commission awarded on 30.08.2018 by the Federal Joint Committee (G-BA).
Pretreated adults with Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML) and limited treatment options
Due to a lack of suitable study data, added benefit not proven in the chronic phase or in the accelaterated phase and blast crisis
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A18-33||Bosutinib (chronic myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|G13-01||Bosutinib - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)||Commission completed|
|A21-79||Bosutinib (chronic myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V||Commission completed|